-
1
-
-
0035883897
-
Rheumatoid arthritis
-
Lee, D. M. & Weinblatt, M. E. Rheumatoid arthritis. Lancet 358, 903-911 (2001).
-
(2001)
Lancet
, vol.358
, pp. 903-911
-
-
Lee, D.M.1
Weinblatt, M.E.2
-
2
-
-
84958107344
-
The effect of a hormone of the adrenal cortex (17-hydroxy-11- dehydrocorticosterone; Compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis
-
Hench, P. S. et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc. Staff Meet. Mayo Clin. 24, 181-197 (1949).
-
(1949)
Proc. Staff Meet. Mayo Clin
, vol.24
, pp. 181-197
-
-
Hench, P.S.1
-
3
-
-
57149112328
-
Issues in the design of new clinical trials for rheumatoid arthritis therapeutics
-
Schwieterman, W. D. Issues in the design of new clinical trials for rheumatoid arthritis therapeutics. Nat. Clin. Pract. Rheumatol. 4, 641-648 (2008).
-
(2008)
Nat. Clin. Pract. Rheumatol
, vol.4
, pp. 641-648
-
-
Schwieterman, W.D.1
-
4
-
-
9244247260
-
Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications
-
O'Dell, J. R. et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 334, 1287-1291 (1996).
-
(1996)
N. Engl. J. Med
, vol.334
, pp. 1287-1291
-
-
O'Dell, J.R.1
-
5
-
-
0028572390
-
Combination of methotrexate and sulphasalazine vs methotrexate alone: A randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy
-
Haagsma, C. J. et al. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. Br. J. Rheumatol. 33, 1049-1055 (1994).
-
(1994)
Br. J. Rheumatol
, vol.33
, pp. 1049-1055
-
-
Haagsma, C.J.1
-
6
-
-
0032957015
-
Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
-
Dougados, M. et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann. Rheum. Dis. 58, 220-225 (1999).
-
(1999)
Ann. Rheum. Dis
, vol.58
, pp. 220-225
-
-
Dougados, M.1
-
7
-
-
0030751946
-
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
-
Boers, M. et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350, 309-318 (1997).
-
(1997)
Lancet
, vol.350
, pp. 309-318
-
-
Boers, M.1
-
8
-
-
0033535754
-
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial
-
Mottonen, T. et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353, 1568-1573 (1999).
-
(1999)
FIN-RACo Trial Group. Lancet
, vol.353
, pp. 1568-1573
-
-
Mottonen, T.1
-
9
-
-
77950307115
-
Treating rheumatoid arthritis to target: Recommendations of an international task force
-
Smolen, J. S. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69, 631-637 (2010).
-
(2010)
Ann. Rheum. Dis
, vol.69
, pp. 631-637
-
-
Smolen, J.S.1
-
10
-
-
3242677099
-
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial
-
Grigor, C. et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263-269 (2004).
-
(2004)
Lancet
, vol.364
, pp. 263-269
-
-
Grigor, C.1
-
11
-
-
27744514865
-
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial
-
Goekoop-Ruiterman, Y. P. et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52, 3381-3390 (2005).
-
(2005)
Arthritis Rheum
, vol.52
, pp. 3381-3390
-
-
Goekoop-Ruiterman, Y.P.1
-
12
-
-
0033524159
-
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial ATTRACT Study Group
-
Maini, R. et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354, 1932-1939 (1999).
-
(1999)
Lancet
, vol.354
, pp. 1932-1939
-
-
Maini, R.1
-
13
-
-
0033574147
-
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
-
Moreland, L. W. et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130, 478-486 (1999).
-
(1999)
Ann. Intern. Med
, vol.130
, pp. 478-486
-
-
Moreland, L.W.1
-
14
-
-
0033611472
-
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
-
Weinblatt, M. E. et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340, 253-259 (1999).
-
(1999)
N. Engl. J. Med
, vol.340
, pp. 253-259
-
-
Weinblatt, M.E.1
-
15
-
-
0037231533
-
Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
-
Weinblatt, M. E. et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48, 35-45 (2003).
-
(2003)
Arthritis Rheum
, vol.48
, pp. 35-45
-
-
Weinblatt, M.E.1
-
16
-
-
33746961890
-
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
-
Cohen, S. B. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54, 2793-2806 (2006).
-
(2006)
Arthritis Rheum
, vol.54
, pp. 2793-2806
-
-
Cohen, S.B.1
-
17
-
-
24944498854
-
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
-
Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353, 1114-1123 (2005).
-
(2005)
N. Engl. J. Med
, vol.353
, pp. 1114-1123
-
-
Genovese, M.C.1
-
18
-
-
52149099504
-
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial
-
Emery, P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67, 1516-1523 (2008).
-
(2008)
Ann. Rheum. Dis
, vol.67
, pp. 1516-1523
-
-
Emery, P.1
-
19
-
-
0014115513
-
Explanatory and pragmatic attitudes in therapeutical trials
-
Schwartz, D. & Lellouch, J. Explanatory and pragmatic attitudes in therapeutical trials. J. Chronic Dis. 20, 637-648 (1967).
-
(1967)
J. Chronic Dis
, vol.20
, pp. 637-648
-
-
Schwartz, D.1
Lellouch, J.2
-
20
-
-
0023185342
-
Equipoise and the ethics of clinical research
-
Freedman, B. Equipoise and the ethics of clinical research. N. Engl. J. Med. 317, 141-145 (1987).
-
(1987)
N. Engl. J. Med
, vol.317
, pp. 141-145
-
-
Freedman, B.1
-
21
-
-
2442642919
-
Appropriate and effective management of rheumatoid arthritis
-
Breedveld, F. C. & Kalden, J. R. Appropriate and effective management of rheumatoid arthritis. Ann. Rheum. Dis. 63, 627-633 (2004).
-
(2004)
Ann. Rheum. Dis
, vol.63
, pp. 627-633
-
-
Breedveld, F.C.1
Kalden, J.R.2
-
22
-
-
33847628013
-
Early rheumatoid arthritis: Strategies for prevention and management
-
Combe, B. Early rheumatoid arthritis: strategies for prevention and management. Best Pract. Res. Clin. Rheumatol. 21, 27-42 (2007).
-
(2007)
Best Pract. Res. Clin. Rheumatol
, vol.21
, pp. 27-42
-
-
Combe, B.1
-
23
-
-
67650129875
-
The BeSt story: On strategy trials in rheumatoid arthritis
-
Klarenbeek, N. B., Allaart, C. F., Kerstens, P. J., Huizinga, T. W. & Dijkmans, B. A. The BeSt story: on strategy trials in rheumatoid arthritis. Curr. Opin. Rheumatol. 21, 291-298 (2009).
-
(2009)
Curr. Opin. Rheumatol
, vol.21
, pp. 291-298
-
-
Klarenbeek, N.B.1
Allaart, C.F.2
Kerstens, P.J.3
Huizinga, T.W.4
Dijkmans, B.A.5
-
24
-
-
63649136121
-
Explanatory and pragmatic attitudes in therapeutical trials
-
Schwartz, D. & Lellouch, J. Explanatory and pragmatic attitudes in therapeutical trials. J. Clin. Epidemiol. 62, 499-505 (2009).
-
(2009)
J. Clin. Epidemiol
, vol.62
, pp. 499-505
-
-
Schwartz, D.1
Lellouch, J.2
-
25
-
-
77953696525
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
-
Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69, 964-975 (2010).
-
(2010)
Ann. Rheum. Dis
, vol.69
, pp. 964-975
-
-
Smolen, J.S.1
-
26
-
-
77953718691
-
Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
-
Knevel, R. et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 69, 987-994 (2010).
-
(2010)
Ann. Rheum. Dis
, vol.69
, pp. 987-994
-
-
Knevel, R.1
-
27
-
-
84874658243
-
-
The CONSORT Group. The CONSORT statement [online] 2013
-
The CONSORT Group. The CONSORT statement [online], http://www.consort- statement.org/consort-statement/(2013).
-
-
-
-
28
-
-
57349108691
-
Improving the reporting of pragmatic trials: An extension of the CONSORT statement
-
Zwarenstein, M. et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 337, a2390 (2008).
-
(2008)
BMJ
, vol.337
-
-
Zwarenstein, M.1
-
31
-
-
0023239521
-
Effect of sulphasalazine on the radiological progression of rheumatoid arthritis
-
Pullar, T., Hunter, J. A. & Capell, H. A. Effect of sulphasalazine on the radiological progression of rheumatoid arthritis. Ann. Rheum. Dis. 46, 398-402 (1987).
-
(1987)
Ann. Rheum. Dis
, vol.46
, pp. 398-402
-
-
Pullar, T.1
Hunter, J.A.2
Capell, H.A.3
-
32
-
-
0020503084
-
Sulphasalazine in rheumatoid arthritis: A double blind comparison of sulphasalazine with placebo and sodium aurothiomalate
-
Pullar, T., Hunter, J. A. & Capell, H. A. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br. Med. J. (Clin. Res. Ed.) 287, 1102-1104 (1983).
-
(1983)
Br. Med. J. (Clin. Res. Ed)
, vol.287
, pp. 1102-1104
-
-
Pullar, T.1
Hunter, J.A.2
Capell, H.A.3
-
33
-
-
0030066368
-
Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis
-
ten Wolde, S. et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 347, 347-352 (1996).
-
(1996)
Lancet
, vol.347
, pp. 347-352
-
-
Ten Wolde, S.1
-
34
-
-
77953706155
-
Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
-
Gaujoux-Viala, C. et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 69, 1004-1009 (2010).
-
(2010)
Ann. Rheum. Dis
, vol.69
, pp. 1004-1009
-
-
Gaujoux-Viala, C.1
-
35
-
-
38749141455
-
Systematic review: Comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis
-
Donahue, K. E. et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann. Intern. Med. 148, 124-134 (2008).
-
(2008)
Ann. Intern. Med
, vol.148
, pp. 124-134
-
-
Donahue, K.E.1
-
36
-
-
0028143212
-
Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis
-
Elliott, M. J. et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125-1127 (1994).
-
(1994)
Lancet
, vol.344
, pp. 1125-1127
-
-
Elliott, M.J.1
-
37
-
-
10744223002
-
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial
-
Klareskog, L. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675-681 (2004).
-
(2004)
Lancet
, vol.363
, pp. 675-681
-
-
Klareskog, L.1
-
38
-
-
31044442965
-
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
-
Breedveld, F. C. et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26-37 (2006).
-
(2006)
Arthritis Rheum
, vol.54
, pp. 26-37
-
-
Breedveld, F.C.1
-
39
-
-
77953694972
-
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of RA
-
Nam, J. L. et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann. Rheum. Dis. 69, 976-986 (2010).
-
(2010)
Ann. Rheum. Dis
, vol.69
, pp. 976-986
-
-
Nam, J.L.1
-
40
-
-
0022627532
-
Rheumatoid arthritis: Treatment which controls the Creactive protein and erythrocyte sedimentation rate reduces radiological progression
-
Dawes, P. T. et al. Rheumatoid arthritis: treatment which controls the Creactive protein and erythrocyte sedimentation rate reduces radiological progression. Br. J. Rheumatol. 25, 44-49 (1986).
-
(1986)
Br. J. Rheumatol
, vol.25
, pp. 44-49
-
-
Dawes, P.T.1
-
41
-
-
0028211156
-
Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants
-
van Leeuwen, M. A. et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J. Rheumatol. 21, 425-429 (1994).
-
(1994)
J. Rheumatol
, vol.21
, pp. 425-429
-
-
Van Leeuwen, M.A.1
-
42
-
-
0033501902
-
Long-term course and outcome of functional capacity in rheumatoid arthritis: The effect of disease activity and radiologic damage over time
-
Drossaers-Bakker, K. W. et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum. 42, 1854-1860 (1999).
-
(1999)
Arthritis Rheum
, vol.42
, pp. 1854-1860
-
-
Drossaers-Bakker, K.W.1
-
43
-
-
3142771252
-
The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: A longitudinal analysis
-
Welsing, P. M. et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum. 50, 2082-2093 (2004).
-
(2004)
Arthritis Rheum
, vol.50
, pp. 2082-2093
-
-
Welsing, P.M.1
-
44
-
-
33749319744
-
Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components
-
Aletaha, D., Smolen, J. & Ward, M. M. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum. 54, 2784-2792 (2006).
-
(2006)
Arthritis Rheum
, vol.54
, pp. 2784-2792
-
-
Aletaha, D.1
Smolen, J.2
Ward, M.M.3
-
45
-
-
3042649468
-
Radiography as primary outcome in rheumatoid arthritis: Acceptable sample sizes for trials with 3 months' follow up
-
Bruynesteyn, K., Landewe, R., van der Linden, S. & van der Heijde, D. Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months' follow up. Ann. Rheum. Dis. 63, 1413-1418 (2004).
-
(2004)
Ann. Rheum. Dis
, vol.63
, pp. 1413-1418
-
-
Bruynesteyn, K.1
Landewe, R.2
Van Der Linden, S.3
Van Der Heijde, D.4
-
48
-
-
73449087363
-
A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals
-
Boers, M. A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals. Ann. Rheum. Dis. 69, 4-6 (2010).
-
(2010)
Ann. Rheum. Dis
, vol.69
, pp. 4-6
-
-
Boers, M.1
-
49
-
-
55849112632
-
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
-
Keystone, E. et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58, 3319-3329 (2008).
-
(2008)
Arthritis Rheum
, vol.58
, pp. 3319-3329
-
-
Keystone, E.1
-
50
-
-
84857697133
-
Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: A randomized trial
-
Bakker, M. F. et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 156, 329-339 (2012).
-
(2012)
Ann. Intern. Med
, vol.156
, pp. 329-339
-
-
Bakker, M.F.1
-
51
-
-
68049124945
-
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
-
van Vollenhoven, R. F. et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 374, 459-466 (2009).
-
(2009)
Lancet
, vol.374
, pp. 459-466
-
-
Van Vollenhoven, R.F.1
-
52
-
-
85027919018
-
Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
-
Kavanaugh, A. et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann. Rheum. Dis. 72, 64-71 (2013).
-
(2013)
Ann. Rheum. Dis
, vol.72
, pp. 64-71
-
-
Kavanaugh, A.1
-
53
-
-
84857410587
-
Lack of head-to-head trials and fair control arms: Randomized controlled trials of biologic treatment for rheumatoid arthritis
-
Estellat, C. & Ravaud, P. Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis. Arch. Intern. Med. 172, 237-244 (2012).
-
(2012)
Arch. Intern. Med
, vol.172
, pp. 237-244
-
-
Estellat, C.1
Ravaud, P.2
-
54
-
-
78651383189
-
Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA
-
Smolen, J. S. et al. Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. Curr. Med. Res. Opin. 27, 315-325 (2011).
-
(2011)
Curr. Med. Res. Opin
, vol.27
, pp. 315-325
-
-
Smolen, J.S.1
-
55
-
-
84870514601
-
Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 ADACTA trial [abstract LB0003]
-
Gabay, C. et al. Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 ADACTA trial [abstract LB0003]. Ann. Rheum. Dis. 71 (Suppl. 3), 152 (2012).
-
(2012)
Ann. Rheum. Dis
, vol.71
, Issue.SUPPL. 3
, pp. 152
-
-
Gabay, C.1
-
56
-
-
84867071979
-
Abatacept SC versus adalimumab on background methotrexate in RA: One year results from the AMPLE study [abstract OP0022]
-
Schiff, M. et al. Abatacept SC versus adalimumab on background methotrexate in RA: one year results from the AMPLE study [abstract OP0022] Ann. Rheum. Dis. 71 (Suppl. 3), 60 (2012).
-
(2012)
Ann. Rheum. Dis
, vol.71
, Issue.SUPPL. 3
, pp. 60
-
-
Schiff, M.1
-
57
-
-
33845508231
-
Making sense of noninferiority: A clinical and statistical perspective on its application to cardiovascular clinical trials
-
Kaul, S. & Diamond, G. A. Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials. Prog. Cardiovasc. Dis. 49, 284-299 (2007).
-
(2007)
Prog. Cardiovasc. Dis
, vol.49
, pp. 284-299
-
-
Kaul, S.1
Diamond, G.A.2
-
58
-
-
38449111304
-
Trend toward noninferiority trials may mean more difficult interpretation of trial results
-
Tuma, R. S. Trend toward noninferiority trials may mean more difficult interpretation of trial results. J. Natl Cancer Inst. 99, 1746-1748 (2007).
-
(2007)
J. Natl Cancer Inst
, vol.99
, pp. 1746-1748
-
-
Tuma, R.S.1
-
59
-
-
80052226713
-
Gain in popularity of noninferiority trial design: Caveat lector
-
Vermeulen, L. Gain in popularity of noninferiority trial design: caveat lector. Pharmacotherapy 31, 831-832 (2011).
-
(2011)
Pharmacotherapy
, vol.31
, pp. 831-832
-
-
Vermeulen, L.1
-
60
-
-
33845880693
-
Non-inferiority trials in oncology: Arbitrary limits, infeasible sample sizes and uninformative data analysis. Is there another way?
-
Carroll, K. J. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. Is there another way? Pharm. Stat. 5, 283-293 (2006).
-
(2006)
Pharm. Stat
, vol.5
, pp. 283-293
-
-
Carroll, K.J.1
Active-Controlled2
-
61
-
-
0037472837
-
Non-inferiority trials: Design concepts and issues-The encounters of academic consultants in statistics
-
D'Agostino, R. B., Sr., Massaro, J. M. & Sullivan, L. M. Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics. Stat. Med. 22, 169-186 (2003).
-
(2003)
Stat. Med
, vol.22
, pp. 169-186
-
-
D'Agostino Sr., R.B.1
Massaro, J.M.2
Sullivan, L.M.3
-
62
-
-
0034687076
-
Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases
-
Ellenberg, S. S. & Temple, R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann. Intern. Med. 133, 464-470 (2000).
-
(2000)
Ann. Intern. Med
, vol.133
, pp. 464-470
-
-
Ellenberg, S.S.1
Temple, R.2
-
63
-
-
0041639486
-
Active-control clinical trials to establish equivalence or noninferiority: Methodological and statistical concepts linked to quality
-
Gomberg-Maitland, M., Frison, L. & Halperin, J. L. Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality. Am. Heart J. 146, 398-403 (2003).
-
(2003)
Am. Heart J
, vol.146
, pp. 398-403
-
-
Gomberg-Maitland, M.1
Frison, L.2
Halperin, J.L.3
-
64
-
-
33745931889
-
Good enough: A primer on the analysis and interpretation of noninferiority trials
-
Kaul, S. & Diamond, G. A. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann. Intern. Med. 145, 62-69 (2006).
-
(2006)
Ann. Intern. Med
, vol.145
, pp. 62-69
-
-
Kaul, S.1
Diamond, G.A.2
-
65
-
-
0034687072
-
Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues
-
Temple, R. & Ellenberg, S. S. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann. Intern. Med. 133, 455-463 (2000).
-
(2000)
Ann. Intern. Med
, vol.133
, pp. 455-463
-
-
Temple, R.1
Ellenberg, S.S.2
-
66
-
-
0037285074
-
Statistical issues on objective, design, and analysis of noninferiority active-controlled clinical trial
-
Tsong, Y., Wang, S. J., Hung, H. M. & Cui, L. Statistical issues on objective, design, and analysis of noninferiority active-controlled clinical trial. J. Biopharm. Stat. 13, 29-41 (2003).
-
(2003)
J. Biopharm. Stat
, vol.13
, pp. 29-41
-
-
Tsong, Y.1
Wang, S.J.2
Hung, H.M.3
Cui, L.4
-
67
-
-
78249278823
-
Is it time to move to active comparator trials in juvenile idiopathic arthritis?: A review of current study designs
-
Ruperto, N. et al. Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs. Arthritis Rheum. 62, 3131-3139 (2010).
-
(2010)
Arthritis Rheum
, vol.62
, pp. 3131-3139
-
-
Ruperto, N.1
-
68
-
-
51749123391
-
Speeding up the evaluation of new agents in cancer
-
Parmar, M. K. et al. Speeding up the evaluation of new agents in cancer. J. Natl Cancer Inst. 100, 1204-1214 (2008).
-
(2008)
J. Natl Cancer Inst
, vol.100
, pp. 1204-1214
-
-
Parmar, M.K.1
-
69
-
-
33746551430
-
-
FDA
-
FDA. Critical Path Opportunities Report [online], http://www.fda.gov/ downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/UCM077254.pdf (2006).
-
(2006)
Critical Path Opportunities Report
-
-
-
70
-
-
78249249606
-
Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group
-
Gallo, P. et al. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group. J. Biopharm. Stat. 20, 1115-1124 (2010).
-
(2010)
J. Biopharm. Stat
, vol.20
, pp. 1115-1124
-
-
Gallo, P.1
-
71
-
-
0035100888
-
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
-
Biomarkers Definitions Working Group
-
Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharm. Ther. 69, 89-95 (2001).
-
(2001)
Clin. Pharm. Ther
, vol.69
, pp. 89-95
-
-
-
72
-
-
84863709923
-
Incorporating biomarkers into clinical trial designs: Points to consider
-
Bradley, E. Incorporating biomarkers into clinical trial designs: points to consider. Nat. Biotechnol. 30, 596-599 (2012).
-
(2012)
Nat. Biotechnol
, vol.30
, pp. 596-599
-
-
Bradley, E.1
-
73
-
-
79957857433
-
The BATTLE trial: Personalizing therapy for lung cancer
-
Kim, E. S. et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 1, 44-53 (2011).
-
(2011)
Cancer Discov
, vol.1
, pp. 44-53
-
-
Kim, E.S.1
-
75
-
-
58149151278
-
The use of genomics in clinical trial design
-
Simon, R. The use of genomics in clinical trial design. Clin. Cancer Res. 14, 5984-5993 (2008).
-
(2008)
Clin. Cancer Res
, vol.14
, pp. 5984-5993
-
-
Simon, R.1
-
76
-
-
42649145667
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Onc. 26, 1626-1634 (2008).
-
(2008)
J. Clin. Onc
, vol.26
, pp. 1626-1634
-
-
Amado, R.G.1
-
78
-
-
8444239359
-
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
-
St Clair, E. W. et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50, 3432-3443 (2004).
-
(2004)
Arthritis Rheum
, vol.50
, pp. 3432-3443
-
-
St Clair, E.W.1
-
79
-
-
54949137664
-
Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis
-
Bejarano, V. et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum. 59, 1467-1474 (2008).
-
(2008)
Arthritis Rheum
, vol.59
, pp. 1467-1474
-
-
Bejarano, V.1
-
80
-
-
48149100741
-
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial
-
Emery, P. et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372, 375-382 (2008).
-
(2008)
Lancet
, vol.372
, pp. 375-382
-
-
Emery, P.1
-
81
-
-
67449124634
-
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID 2 study. A randomised controlled trial
-
Smolen, J. et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann. Rheum. Dis. 68, 797-804 (2009).
-
(2009)
Ann. Rheum. Dis
, vol.68
, pp. 797-804
-
-
Smolen, J.1
-
82
-
-
84871093047
-
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
-
Dougados, M. et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann. Rheum. Dis. 72, 43-50 (2012).
-
(2012)
Ann. Rheum. Dis
, vol.72
, pp. 43-50
-
-
Dougados, M.1
-
83
-
-
41849120516
-
Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
-
Genovese, M. C. et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann. Rheum. Dis. 67, 547-554 (2008).
-
(2008)
Ann. Rheum. Dis
, vol.67
, pp. 547-554
-
-
Genovese, M.C.1
-
84
-
-
67650379733
-
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial
-
Smolen, J. S. et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374, 210-226 (2009).
-
(2009)
Lancet
, vol.374
, pp. 210-226
-
-
Smolen, J.S.1
-
86
-
-
80052341629
-
The OMERACT ultrasound task force-status and perspectives
-
Naredo, E. et al. The OMERACT ultrasound task force-status and perspectives. J. Rheumatol. 38, 2063-2067 (2011).
-
(2011)
J. Rheumatol
, vol.38
, pp. 2063-2067
-
-
Naredo, E.1
-
87
-
-
80052050619
-
Development and preliminary validation of a magnetic resonance imaging joint space narrowing score for use in rheumatoid arthritis: Potential adjunct to the OMERACT RA MRI scoring system
-
Ostergaard, M. et al. Development and preliminary validation of a magnetic resonance imaging joint space narrowing score for use in rheumatoid arthritis: potential adjunct to the OMERACT RA MRI scoring system. J. Rheumatol. 38, 2045-2050 (2011).
-
(2011)
J. Rheumatol
, vol.38
, pp. 2045-2050
-
-
Ostergaard, M.1
-
88
-
-
80052320868
-
OMERACT 10 Sharp Symposium: Important findings in examination of imaging methods for measurement of joint damage in rheumatoid arthritis
-
Strand, V. et al. OMERACT 10 Sharp Symposium: important findings in examination of imaging methods for measurement of joint damage in rheumatoid arthritis. J. Rheumatol. 38, 2009-2013 (2011).
-
(2011)
J. Rheumatol
, vol.38
, pp. 2009-2013
-
-
Strand, V.1
-
89
-
-
84860390334
-
Predictive biomarkers: A paradigm shift towards personalized cancer medicine
-
La Thangue, N. B. & Kerr, D. J. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Onc. 8, 587-596 (2011).
-
(2011)
Nat. Rev. Clin. Onc
, vol.8
, pp. 587-596
-
-
La Thangue, N.B.1
Kerr, D.J.2
-
90
-
-
84863475669
-
On the independence of data monitoring committee in adaptive design clinical trials
-
Chow, S.C., Corey, R. & Lin, M. On the independence of data monitoring committee in adaptive design clinical trials. J. Biopharm. Stat. 22, 853-867 (2012).
-
(2012)
J. Biopharm. Stat
, vol.22
, pp. 853-867
-
-
Chow, S.C.1
Corey, R.2
Lin, M.3
|